In three trials, LEADER, SUSTAIN 6, and REWIND, the GLP-1RA was superior to placebo ( p = .01, p = .02, and p = .026, respectively, for superiority), showing lower risk of the composite MACE endpoint: liraglutide hazard ratio (HR) 0.87 (95% confidence interval [CI]: 0.780.97), sc semaglutide HR 0.74 (95% CI: 0.580.95), and dulaglutide HR 0.88 (95% CI: 0.790.99) (Figure 1)
LEMA valuta i nuovi farmaci tramite una procedura centralizzata: le aziende presentano dati completi su qualit, efficacia e sicurezza
"EcoWatch and Waterkeeper Launch News Website"
Free Radic Biol Med 115:92104
Furthermore, acquired immunity develops and matures in response to exposure to gut microbiota [149]
L karnitin taurin , ieriindeki gl antioksidanlar ve vitaminler sayesinde baklk sistemini destekler